ZIVO Bioscience Provides Special Letter to Shareholders

Why It Matters

By going private, ZIVO can redirect resources toward commercializing its ag‑tech and animal‑health pipelines, improving cash generation potential. This move reflects a broader trend where early‑stage biotech firms prioritize operational focus over public‑market visibility.

Key Takeaways

• ZIVO will deregister and cease SEC reporting.
• Cost savings aim to redirect capital to growth.
• Anticipated AgTech revenue to achieve first positive cash flow.
• Animal health partnerships progressing; licensing discussions upcoming.
• Board compensation eliminated; CEO reinvests personal capital.

Pulse Analysis

The decision to deregister reflects a growing pattern among small‑cap biotech firms that find SEC compliance, audit fees, and investor‑relations costs disproportionate to their cash reserves. For ZIVO, eliminating these expenses means more of its limited capital can be allocated to R&D and market entry activities rather than to third‑party service providers. This strategic shift also reduces the need for frequent equity raises, which have historically diluted existing shareholders and created a cycle of financing that hampers long‑term value creation.

ZIVO’s near‑term growth narrative centers on its AgTech product line, which is poised to generate revenue through an established distribution partner. Management projects that this inflow, combined with lower operating overhead, will push the company into positive cash flow for the first time. Simultaneously, the animal‑health division is advancing non‑antibiotic immune‑modulating technology, with global pharma players conducting due diligence and preparing for licensing negotiations. The microalgae ingredient ZIVO LIFE™ is also attracting formulators worldwide, prompting the firm to scale production capacity in anticipation of rising demand.

Governance changes underscore the board’s commitment to shareholder alignment: board compensation has been removed, and the CEO continues to invest personal capital at market rates. While the move eliminates public‑market scrutiny, it also places greater responsibility on the company to meet its forward‑looking revenue milestones. Investors should monitor the execution of distribution agreements, progress of animal‑health licensing talks, and the company’s ability to sustain cash flow without the safety net of public financing. Success in these areas could validate the private‑company strategy and set a precedent for similar biotech firms.